CLSD
Clearside Biomedical, Inc.NASDAQHealthcareAs of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-0.03
P/S
0.49
EV/EBITDA
-3.93
DCF Value
$-8.93
FCF Yield
-1336.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.6%
Operating Margin
-689.8%
Net Margin
-780.9%
ROE
55.5%
ROA
-223.3%
ROIC
-248.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $201.0K | $-6.0M | $-1.14 |
| Q2 2025 | $492.0K | $-4.5M | $-0.87 |
| Q1 2025 | $2.3M | $-8.2M | $-1.65 |
| Q4 2024 | $306.0K | $-7.3M | $-1.44 |
Analyst Ratings
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.79
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.